LY 353433

Drug Profile

LY 353433

Latest Information Update: 22 Aug 2001

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Indazoles; Polycyclic bridged compounds
  • Mechanism of Action Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Gastro-oesophageal reflux; Irritable bowel syndrome; Non-ulcer dyspepsia

Most Recent Events

  • 22 Aug 2001 No-Development-Reported for Gastro-oesophageal reflux in USA (PO)
  • 22 Aug 2001 No-Development-Reported for Irritable bowel syndrome in USA (PO)
  • 22 Aug 2001 No-Development-Reported for Non-ulcer dyspepsia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top